Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA/Tonalin® FFA 80) and Probiotics (Vivomixx®/VSL#3) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis

NCT05920018 is registered in ClinicalTrials.gov with Universität Münster as lead sponsor.

NCT NCT05920018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05920018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA/Tonalin® FFA 80) and Probiotics (Vivomixx®/VSL#3) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis
Lead sponsor
Universität Münster
Phase
Not applicable
Overall status
Unknown status
Start date
October 2, 2023
Completion date
February 28, 2025
Enrollment
100 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing-remitting